From 2017 to 2023, a decreasing trend in the percentage of “Full Innovative” assessments was observed (slope = −5.96), but it was not statistically significant ( p = 0.62), suggesting year-to-year fluctuations rather than a consistent pattern.
← all excerpts
The Italian Assessment System for Innovative Medicines: An 8-Year Retrospective Analysis of Outcomes, Criteria, Timelines and Funding Dynamics.
2
—
—
The sentences
Other variables, including TN, oncologic indication, and ATMP status, did not reach statistical significance.